2 not yet recruiting. 1 Not applicable, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 1 | Not yet recruiting 1 |
| Phase 2 | 1 | Not yet recruiting 1 |
Follow Jin LI: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Single-arm, Multicenter, Phase II Clinical Study of Camrelizumab Combined With Famitinib in Adjuvant Therapy After Radical Resection of Cervical Cancer Camrelizumab, famotinib - Cervical Cancer, Radical Surgery | Not applicable | Not yet recruiting | Jin LI | 30 | 2026-04-01 | 2026-03-12 |
| Fluzoparib Combined With Apatinib in Relapsed Ovarian Carcinoma Maintenance Treatment Fluzoparib, Apatinib - Relapsed Ovarian Cancer | Phase 2 | Not yet recruiting | Jin Li | 54 | 2023-10-30 | 2023-10-13 |
Ovarian Neoplasms (1) · Uterine Cervical Neoplasms (1)
apatinib (1) · camrelizumab (1) · fluzoparib (1)
China (1)